

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				Complete if Known	
				Application Number	Not yet known 10/793403
				Filing Date	Herein 12/22/03
				First Name Inventor	Wolfgang Guba
				Group Art Unit	1626
Examiner Name	Stockton				
Sheet 1 of 2	Attorney Docket Number		21553		









U.S. PATENT DOCUMENTS					
Examiner Initials ¹	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited document MM-DD-YYYY
		Number	Kind Code ² (if known)		
	A1	5624941		Sanofi	04-29-1997
	A2	3940418		G.D. Searle & Co.	02-24-1976
	A3	5596106		Eli Lilly and Company	01-21-1997

FOREIGN PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document			Date of Publication of Cited Document MM-DD-YYYY	T ⁴
		Office ³	Number ⁴	Kind Code ² (if known)		
	B1		WO0015609		Aventis Pharma S.A. 03-23-2000	✓
	B2		WO0164634		Aventis Pharma S.A. 09-07-2001	✓
	B3		WO0228346		Aventis Pharma S.A. 04-11-2002	✓
	B4		WO0164632		Aventis Pharma S.A. 09-07-2001	✓
	B5		WO0164633		Aventis Pharma S.A. 09-07-2001	✓
	B6		WO0170700		Solvay Pharmaceuticals B.V. 09-27-2001	
	B7		WO0132663		Sanofi-Synthelabo 05-10-2001	✓
	B8		WO0046209		Sanofi-Synthelabo 08-01-2000	✓
	B9		WO9719063		Sanofi 05-29-1997	
	B10		EP658546		Sanofi-Synthelabo 06-21-1995	✓
	B11		EP656354		Sanofi 06-07-1995	✓
	B12		EP576357		Sanofi 12-29-1993	✓
	B13		WO9602248		Eli Lilly and Company 02-01-1996	✓
Examiner Signature		Laurie J. Stockton 2/17/05				

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
²Unique citation designation number. ³See attached Kinds of U.S. Patent Documents. ⁴Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷Applicant is to place a check mark here if English language Translation or abstract is attached.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			Complete if Known		
			Application Number	Not yet known 10/743403	
			Filing Date	Herein - 12/22/03	
			First Name Inventor	Wolfgang Guba	
			Group Art Unit		
			Examiner Name		
Sheet	2	Of	2	Attorney Docket Number	21553

NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	C1	PACHECO, M., ET AL., Aminoalkylindoles: Actions on Specific G-Protein-Linked Receptors, Journal of Pharmacology and Experimental Therapeutics, 1991, pp. 170-183, v. 257(1)	
	C2	CASIANO, F.M., ET AL., Putative Aminoalkylindoles (AAI) Antagonists, Problems of Drug Dependence 1990: Proceedings of the 52 nd Annual Scientific Meeting The Committee on Problems of Drug Dependence, 1991, pp. 295-296, v. 105	
	C3	HOSOHATA, K., ET AL., AM630 is a Competitive Cannabinoid Receptor Antagonist in the Guinea Pig Brain, Life Sciences, 1997, pp. 115-118, v. 61(9)	
	C4	PERTWEE, R., ET AL., AM630, A Competitive Cannabinoid Receptor Antagonist, Life Sciences, 1995, pp. 1949-1955, v. 56(23/24)	
	C5	FELDER, C.C., ET AL., LY320135, a Novel Cannabinoid CB1 Receptor Antagonist, Unmasks Coupling of the CB1 Receptor to Stimulation of cAMP Accumulation, Journal of Pharmacology and Experimental Therapeutics, 1998, pp. 291-297, v. 284(1)	
	C6	KANYONYO, M. ET AL., 3-Alkyl-(5,5'-Diphenyl) Imidazolidinediones As New Cannabinoid Ligands, Bioorganic & Medicinal Chemistry Letters, 1999, pp.2233-2236, v. 9	
	C7	OOMS, F., ET AL., Exploration of the Pharmacophore of 3-Alkyl-5-Arylimidazolidinediones as New CB ₁ Cannabinoid Receptor Ligands and Potential Antagonists: Synthesis, Lipophilicity, Affinity, and Molecular Modeling, J. Med. Chem., 2002, pp.1748-1756, v. 45(9)	
Examiner Signature			DATE CONSIDERED
			2/17/05

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Unique citation designation number. ³Applicant is to place a check mark here if English language Translation or abstract is attached.

[illegible]

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation or abstract is attached.

142227